Format

Send to

Choose Destination
Endocr Relat Cancer. 2011 Jun 8;18(3):R79-89. doi: 10.1530/ERC-10-0162. Print 2011 Jun.

A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer.

Author information

1
Department of Medical Oncology, Paul Strauss Cancer Center, and University of Strasbourg, 3 rue de la Porte de l'Hôpital - BP42, F-67065 Strasbourg, France. tpetit@strasbourg.fnclcc.fr

Abstract

The introduction of aromatase inhibitors (AI) has provided more options for adjuvant treatment of postmenopausal women; they are associated with improved disease-free survival, but less commonly with improvements in overall survival. Current evidence suggests that women at high risk of recurrence, especially those with node-positive disease, should receive an AI for 2 years as part of their treatment, but routine prescription of AIs to postmenopausal patients with low-risk disease is not appropriate. Not only the expected benefits but also the specific toxicity of the prescribed hormone therapy, and its cost, should be considered when selecting treatment.

PMID:
21502311
DOI:
10.1530/ERC-10-0162
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center